These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38453363)

  • 1. Prognostic Performance of RECIP 1.0 Based on [
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
    J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
    Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
    J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Tumor Volume Assessment on PSMA PET After
    Kind F; Eder AC; Jilg CA; Hartrampf PE; Meyer PT; Ruf J; Michalski K
    J Nucl Med; 2023 Apr; 64(4):605-610. PubMed ID: 36302658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
    Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
    Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
    J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RECIP 1.0 Predicts Progression-Free Survival After [
    Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
    J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 8. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
    J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUV
    Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Schlötelburg W; Michalski K; Rowe SP; Pomper MG; Buck AK; Eberlein U; Werner RA
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3465-3474. PubMed ID: 37272956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
    Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
    Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO
    Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
    Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended therapy with [
    Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Visually Calculated SUV
    Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
    J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative
    Kuo PH; Morris MJ; Hesterman J; Kendi AT; Rahbar K; Wei XX; Fang B; Adra N; Garje R; Michalski JM; Chi K; de Bono J; Fizazi K; Krause B; Sartor O; Tagawa ST; Ghebremariam S; Brackman M; Wong CC; Catafau AM; Benson T; Armstrong AJ; Herrmann K
    Radiology; 2024 Aug; 312(2):e233460. PubMed ID: 39162634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.